Align Technology/$ALGN
1D1W1MYTD1Y5YMAX
Capital at risk
About Align Technology
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
- Ticker
- $ALGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 20,435
- Headquarters
- Tempe, United States
- Website
- www.aligntech.com
Align Technology Metrics
BasicAdvanced
$10B
25.64
$5.76
1.64
-
Price and volume
Market cap
$10B
Beta
1.64
52-week high
$200.44
52-week low
$122.00
Average daily volume
842K
Financial strength
Current ratio
1.395
Quick ratio
1.179
Long term debt to equity
0.02
Total debt to equity
0.029
Profitability
EBITDA (TTM)
925.144
Gross margin (TTM)
70.74%
Net profit margin (TTM)
9.99%
Operating margin (TTM)
18.42%
Effective tax rate (TTM)
27.30%
Revenue per employee (TTM)
$200,000
Management effectiveness
Return on assets (TTM)
7.54%
Return on equity (TTM)
10.15%
Valuation
Price to earnings (TTM)
25.642
Price to revenue (TTM)
2.558
Price to book
2.49
Price to tangible book (TTM)
2.89
Price to free cash flow (TTM)
16.714
Free cash flow yield (TTM)
5.98%
Free cash flow per share (TTM)
8.831
Growth
Revenue change (TTM)
4.41%
Earnings per share change (TTM)
-2.77%
3-year revenue growth (CAGR)
3.47%
10-year revenue growth (CAGR)
15.91%
3-year earnings per share growth (CAGR)
12.31%
10-year earnings per share growth (CAGR)
10.87%
What the Analysts think about Align Technology
Analyst ratings (Buy, Hold, Sell) for Align Technology stock.
Analyst projections of the future price of Align Technology stock.
Bulls say / Bears say
Q2 2026 produced record revenue of $1.06 billion, with Clear Aligner revenue up 8.2% and shipments up 7.4% year over year, supported by double-digit international growth and stable North American performance. (Align Technology)
Management reaffirmed its 2026 outlook, expects roughly 100 basis points of operating-margin improvement, and plans to repurchase $400 million to $500 million of stock in 2026—supportive of per-share earnings and capital returns. (SEC filing)
Align won a first-instance patent-infringement judgment against Angelalign in China, following a European preliminary injunction, strengthening the company’s ability to defend its digital orthodontics technology against a key competitor. (Align Technology)
Systems and Services revenue fell 10.8% year over year in Q2 2026, while Align expects continued mix shifts toward lower-priced scanners and leasing/rental models—potentially pressuring near-term revenue quality and margins. (Align Technology)
Align expects approximately $90 million to $110 million of 2026 operating-margin charges from restructuring, accelerated depreciation, legal settlements, and related items, creating meaningful near-term earnings volatility. (SEC filing)
The UK Upper Tribunal ruling requires 20% VAT on applicable Invisalign aligners and Vivera retainers from September 7, 2026; Align recorded an estimated $37.5 million liability and intends to appeal, leaving additional regulatory and demand risk. (Align Technology)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Align Technology Financial Performance
Revenues and expenses
Align Technology Earnings Performance
Company profitability
Upcoming events
No upcoming events
Align Technology News
AllArticlesVideos
Funds containing Align Technology
AllEURGBPUSD
Fund name | Fund size | $ALGN weighting |
|---|---|---|
iShares AI Adopters and Applications€AIAA | €169M | 0.19% |
iShares AI Adopters and Applications£AIAA | £145M | 0.19% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.17% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.17% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.